U.S. Advanced Therapy Medicinal Products CDMO Market (2024 - 2030) Size, Share & Trends Analysis Report By Product (Gene Therapy, Cell Therapy), By Phase, By Indication, And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                     1.1. Market Segmentation & Scope
                     1.2. Segment Definitions
                         1.2.1. Product
                         1.2.2. Phase
                         1.2.3. Indication
                         1.2.4. Estimates and forecasts timeline
                     1.3. Research Methodology
                     1.4. Information Procurement
                         1.4.1. Purchased database
                         1.4.2. GVR’s internal database
                         1.4.3. Secondary sources
                         1.4.4. Primary research
                         1.4.5. Details of primary research
                     1.5. Information or Data Analysis
                         1.5.1. Data analysis models
                     1.6. Market Formulation & Validation
                     1.7. Model Details
                         1.7.1. Commodity flow analysis (Model 1)
                         1.7.2. Approach 1: Commodity flow approach
                         1.7.3. Volume price analysis (Model 2)
                         1.7.4. Approach 2: Volume price analysis
                     1.8. List of Secondary Sources
                     1.9. List of Primary Sources
                     1.10. Objectives
Chapter 2. Executive Summary
                     2.1. Market Outlook
                     2.2. Segment Outlook
                         2.2.1. Product Outlook
                         2.2.2. Phase Outlook
                         2.2.3. Indication Outlook
                     2.3. Competitive Insights
Chapter 3. U.S. Advanced Therapy Medicinal Products CDMO Market Variables, Trends & Scope
                     3.1. Market Lineage Outlook
                         3.1.1. Parent market outlook
                         3.1.2. Related/ancillary market outlook
                     3.2. Market Dynamics
                         3.2.1. Market driver analysis
                         3.2.2. Market restraint analysis
                         3.2.3. Market opportunity analysis
                     3.3. U.S. Advanced Therapy Medicinal Products CDMO Market Analysis Tools
                         3.3.1. Industry Analysis - Porter’s
                             3.3.1.1. Supplier power
                             3.3.1.2. Buyer power
                             3.3.1.3. Substitution threat
                             3.3.1.4. Threat of new entrant
                             3.3.1.5. Competitive rivalry
                         3.3.2. PESTEL Analysis
                             3.3.2.1. Political landscape
                             3.3.2.2. Technological landscape
                             3.3.2.3. Economic landscape
Chapter 4. U.S. Advanced Therapy Medicinal Products CDMO Market: Product Estimates & Trend Analysis
                     4.1. U.S. Advanced Therapy Medicinal Products CDMO Market: Product Dashboard
                     4.2. U.S. Advanced Therapy Medicinal Products CDMO Market: Product Movement Analysis
                     4.3. U.S. Advanced Therapy Medicinal Products CDMO Market Size & Forecasts and Trend Analyses, 2018 to 2030
                     4.4. Gene Therapy
                         4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                     4.5. Cell Therapy
                         4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                     4.6. Tissue Engineered
                         4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                     4.7. Other Products
                         4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. U.S. Advanced Therapy Medicinal Products CDMO Market: Phase Estimates & Trend Analysis
                     5.1. U.S. Advanced Therapy Medicinal Products CDMO Market: Phase Dashboard
                     5.2. U.S. Advanced Therapy Medicinal Products CDMO Market: Phase Movement Analysis
                     5.3. U.S. Advanced Therapy Medicinal Products CDMO Market Size & Forecasts and Trend Analyses, 2018 to 2030
                     5.4. Phase I
                         5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                     5.5. Phase II
                         5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                     5.6. Phase III
                         5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                     5.7. Phase IV
                         5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. U.S. Advanced Therapy Medicinal Products CDMO Market: Indication Estimates & Trend Analysis
                     6.1. U.S. Advanced Therapy Medicinal Products CDMO Market: Indication Dashboard
                     6.2. U.S. Advanced Therapy Medicinal Products CDMO Market: Indication Movement Analysis
                     6.3. U.S. Advanced Therapy Medicinal Products CDMO Market Size & Forecasts and Trend Analyses, 2018 to 2030
                     6.4. Oncology
                         6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                     6.5. Cardiology
                         6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                     6.6. Central Nervous System
                         6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                     6.7. Musculoskeletal
                         6.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                     6.8. Infectious Disease
                         6.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                     6.9. Dermatology
                         6.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                     6.10. Endocrine, Metabolic, Genetic
                         6.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                     6.11. Immunology & Inflammation
                         6.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                     6.12. Opthalmology
                         6.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                     6.13. Haematology
                         6.13.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                     6.14. Gasteroenterology
                         6.14.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                     6.15. Other Indications
                         6.15.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
                     7.1. Recent Developments & Impact Analysis, By Key Market Participants
                     7.2. Company/Competition Categorization
                     7.3. Vendor Landscape
                         7.3.1. List of key distributors and channel partners
                         7.3.2. Key customers
                         7.3.3. Key company market share analysis, 2023
                         7.3.4. Celonic
                             7.3.4.1. Company overview
                             7.3.4.2. Financial performance
                             7.3.4.3. Product benchmarking
                             7.3.4.4. Strategic initiatives
                         7.3.5. Bio Elpida
                             7.3.5.1. Company overview
                             7.3.5.2. Financial performance
                             7.3.5.3. Product benchmarking
                             7.3.5.4. Strategic initiatives
                         7.3.6. CGT Catapult
                             7.3.6.1. Company overview
                             7.3.6.2. Financial performance
                             7.3.6.3. Product benchmarking
                             7.3.6.4. Strategic initiatives
                         7.3.7. Rentschler Biopharma SE
                             7.3.7.1. Company overview
                             7.3.7.2. Financial performance
                             7.3.7.3. Product benchmarking
                             7.3.7.4. Strategic initiatives
                         7.3.8. AGC Biologics
                             7.3.8.1. Company overview
                             7.3.8.2. Financial performance
                             7.3.8.3. Product benchmarking
                             7.3.8.4. Strategic initiatives
                         7.3.9. Catalent
                             7.3.9.1. Company overview
                             7.3.9.2. Financial performance
                             7.3.9.3. Product benchmarking
                             7.3.9.4. Strategic initiatives
                         7.3.10. Lonza
                             7.3.10.1. Company overview
                             7.3.10.2. Financial performance
                             7.3.10.3. Product benchmarking
                             7.3.10.4. Strategic initiatives
                         7.3.11. WuXi Advanced Therapies
                             7.3.11.1. Company overview
                             7.3.11.2. Financial performance
                             7.3.11.3. Product benchmarking
                             7.3.11.4. Strategic initiatives
                         7.3.12. BlueReg
                             7.3.12.1. Company overview
                             7.3.12.2. Financial performance
                             7.3.12.3. Product benchmarking
                             7.3.12.4. Strategic initiatives
                         7.3.13. Minaris Regenerative Medicine
                             7.3.13.1. Company overview
                             7.3.13.2. Financial performance
                             7.3.13.3. Product benchmarking
                             7.3.13.4. Strategic initiatives
                         7.3.14. Patheon
                             7.3.14.1. Company overview
                             7.3.14.2. Financial performance
                             7.3.14.3. Product benchmarking
                             7.3.14.4. Strategic initiatives

List of Tables

Table 1 List of abbreviation
Table 2 U.S. advanced therapy medicinal products CDMO market, 2018 - 2030 (USD Million)
Table 3 U.S. advanced therapy medicinal products CDMO market, by product, 2018 - 2030 (USD Million)
Table 4 U.S. advanced therapy medicinal products CDMO market, by phase, 2018 - 2030 (USD Million)
Table 5 U.S. advanced therapy medicinal products CDMO market, by indication, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 U.S. advanced therapy medicinal products CDMO market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Competitive landscape snapshot
Fig. 10 Product and stage segment snapshot
Fig. 11 Sales channel segment snapshot
Fig. 12 Market dynamics
Fig. 13 Porter’s five forces analysis
Fig. 14 PESTLE analysis
Fig. 15 U.S. advanced therapy medicinal products CDMO market: Product outlook and key takeaways
Fig. 16 U.S. advanced therapy medicinal products CDMO market: Product movement analysis
Fig. 17 Gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 18 Cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 Tissue engineered market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Other products market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 U.S. advanced therapy medicinal products CDMO market: Phase outlook and key takeaways
Fig. 22 U.S. advanced therapy medicinal products CDMO market: Phase movement analysis
Fig. 23 Phase I market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Phase II market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Phase III market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Phase IV market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 U.S. advanced therapy medicinal products CDMO market: Indication outlook and key takeaways
Fig. 28 U.S. advanced therapy medicinal products CDMO market: Indication movement analysis
Fig. 29 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Cardiology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Central nervous system market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Musculoskeletal market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Infectious disease market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Dermatology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Endocrine, metabolic, genetic market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Immunology & inflammation market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Opthalmology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Haematology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Gasteroenterology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Other indications market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Company market share analysis, 2023
Fig. 42 Strategic framework